INCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AG

Financial Performance:

• No specific revenue, earnings, or cash flow figures were disclosed in the transcript, as the company is focused on clinical development and early-stage revenue.
• The company highlighted a pipeline targeting approximately 250,000 new patients annually across three key indications: MSS colorectal cancer, KRAS G12D pancreatic cancer, and CCNE1-overexpressing ovarian cancer.
• Capital allocation is directed toward advancing two late-stage assets (890 and 734) and expanding a GI oncology franchise, with existing revenue generated from the approved product Zioistina for anal and cervical cancer.

Guidance and Future Outlook:

• Top-line data for the Phase 3 DAWN-303 study (734 in pancreatic cancer) is expected in 2028.
• Top-line data for the Phase 3 NIXER-0303 study (890 in colorectal cancer) is projected for 2029.
• An adjuvant Phase 3 study for 734 in pancreatic cancer is planned to commence in early 2027.
• A pivotal Phase 3 study for 734 in second/third-line colorectal cancer is scheduled to start in the first half of 2027.
• An adjuvant proof-of-concept study for 890 in colorectal cancer (targeting ctDNA-positive patients post-surgery) has already commenced.

Business Segments and Product Lines:

• Asset 890 (INC-A33890): A bispecific antibody targeting TGF-beta R2 and PD-1. Early Phase 1/2 data in first-line MSS colorectal cancer (FOLFOX-BEV backbone) showed a 71% response rate (ORR), 100% disease control rate, and 81% six-month PFS. High activity noted in patients with liver metastases (83% ORR).
• Asset 734 (INC-161734): A selective KRAS G12D on-off inhibitor. In first-line pancreatic cancer, combined with Gemcitabine/Nab-paclitaxel or Modified FOLFIRINOX, it demonstrated ORRs of 69% and 89% respectively, with 6-month PFS of 80-90%. In second-line colorectal cancer combined with Cetuximab, it showed a 36% ORR (vs <5% historical standard of care) and median PFS of 7.2 months.
• Asset 667: A CDK2 inhibitor currently in pivotal trials for ovarian cancer (CCNE1 overexpressing).
• Strategic Focus: Building a world-class solid tumor franchise with a primary emphasis on gastrointestinal (GI) oncology, specifically expanding into adjuvant settings and novel combinations (e.g., with anti-CTLA-4, EGFR antibodies, and ADCs).

Market and Competitive Landscape:

• Pancreatic Cancer: Marketed as a "very lethal disease" with a 5-year survival of ~5% and Stage 4 survival of 3%. Current standard of care offers 20-30% response rates and median survival of ~1 year.
• Colorectal Cancer: 85% of cases are MSS and unresponsive to current checkpoint inhibitors (PD-1 alone).
• Competition: The company views the KRAS G12D space as a race but believes its "on-off" mechanism and deep responses (near 100% disease control in CRC) differentiate it. Management notes that their P3 studies are enrolling globally and rapidly.
• TGF-beta Landscape: Management differentiates 890 from previous systemic TGF-beta inhibitors by using a bispecific approach that limits toxicity while targeting the tumor microenvironment, addressing the high prevalence of liver metastases which are typically immune-excluded.

Risks and Challenges:

• Safety Profile: Managing GI toxicities (nausea, vomiting, diarrhea) and potential immune-related adverse events; however, no fatal events or dose-limiting toxicities (DLTs) have been observed in the presented cohorts.
• Cardiac Safety: Four cases of asymptomatic myocarditis (incidence <1%) were reported in the 890 program, comparable to background rates for PD-1 inhibitors.
• Clinical Trial Success: The Phase 3 studies are powered to beat historical benchmarks; failure to maintain the observed response rates or durability could impact approval prospects.
• Competitive Pressure: The KRAS G12D and TGF-beta landscapes are crowded with multiple programs, requiring strong clinical differentiation and potential first-mover advantage to establish usage patterns.

Management Commentary and Tone:

• Tone: Highly confident and optimistic. Management repeatedly used terms like "world-class," "de-risking," and "compelling data."
• Strategy: Emphasis on "first-mover advantage" and the ability to intervene early in the treatment sequence (adjuvant settings) where patient benefit and commercial opportunity are maximized.
• Development Philosophy: Highlighted internal discovery success (assets discovered and developed internally), contrasting with reliance on licensing.
• Differentiation: Strong belief that the "on-off" inhibition mechanism for KRAS G12D and the bispecific nature of 890 provide a therapeutic advantage over competitors' mechanisms.

Analyst Questions and Answers:

• Competitive Differentiation: Analysts asked about the advantage of the "on-off" inhibitor vs. "on-only" competitors. Management explained that "on-off" coverage ensures maximal inhibition across the entire dosing interval, potentially leading to deeper and more durable responses.
• Combination Partners: Clarified that while a Pan-RAS inhibitor combination is being considered, it is not yet selected; the priority is advancing existing collaborations with BMS (PRMT5 inhibitor) and Genmab (pedocentamab) in 2027.
• Biomarkers: Confirmed that clearance of the KRAS G12D allele in circulating tumor DNA (ctDNA) correlates strongly with clinical response and is a key biomarker being tracked.
• OS Requirement: Confirmed that Overall Survival (OS) is a primary endpoint for the Phase 3 pancreatic trial, but Progression-Free Survival (PFS) and Objective Response Rate (ORR) are also critical for potential accelerated approval pathways.
• Safety Benchmarking: Management noted that relative dose intensities for 734 combinations (67-69%) are comparable to competitor data and standard of care, arguing that the efficacy gain outweighs minor reductions in dose intensity.
• Myocarditis: Addressed that the low incidence of myocarditis in the 890 program is consistent with background rates for PD-1 inhibitors and does not represent a new safety signal.

Other Key Points:

• Collaborations: Announced new collaborations for 734 with BMS (nevelimetastat), Synovyma (SFV1521), and Genmab (pedocentamab).
• Biology Focus: Emphasized the biological rationale for targeting TGF-beta in liver metastases due to high receptor expression and immune exclusion in these tumors.
• Global Enrollment: Both Phase 3 studies are enrolling globally, with 734's pancreatic study expected to complete accrual rapidly.
• Internal Capabilities: Stressed the company's ability to discover novel therapeutics internally, citing the CSO and specific development teams as key drivers of success.